In a nutshell This study wanted to find out if patients with melanoma who had immune system side effects after treatment with nivolumab (Opdivo) had better outcomes than patients without side effects. The study found that the patients who had side effects from using nivolumab ended up with better responses to treatment and...
Read More
In a nutshell This study investigated whether there was a relationship between specific tumor characteristics (biomarkers) in melanoma patients and response to anti-PD-1 immunotherapy. This study found that patients with certain tumor characteristics had a better response to anti-PD-1 immunotherapy and experienced increased survival. Some background...
Read More
In a nutshell This study examined the side effects and health related quality of life (HRQL) of advanced melanoma patients treated with cobimetinib (Cotellic) plus vemurafenib (Zelboraf). Researchers suggested that these patients maintained their HRQL when compared with patients treated with vemurafenib alone. Some background Prior studies...
Read More
In a nutshell This study investigated the effectiveness and safety of the combined treatment with ipilimumab and pembrolizumab in advanced melanoma patients. Researchers suggested that the combined treatment improves cancer outcomes with manageable side effects. Some background The use of immunotherapy, such...
Read More
In a nutshell This study reviewed the currently available treatments for melanoma brain metastasis (MBM; spread to the brain). Researchers reported that treatment should be personalized for the different types of patients. Some background Melanoma has the highest risk of spreading to the brain among all common cancer types. Until the last...
Read More
In a nutshell This study investigated the negative side effects of targeted therapy to treat elderly and younger metastatic (spread to other parts of the body) colorectal cancer patients. Researchers suggested that side effects were different between these patients. Some background Colorectal cancer is one of the most common cancers worldwide....
Read More
In a nutshell This study investigated the effect of nivolumab (Opdivo) in patients with progressive melanoma after ipilimumab (Yervoy) treatment. Researchers suggested that nivolumab treatment is associated with better response compared with chemotherapy. Some background Recent new therapies, such as immunotherapy, have changed the treatment of...
Read More
In a nutshell This review investigated the effectiveness of PD-1 agents in the treatment of melanoma. Researchers suggested that treatment with these agents is associated with improved cancer outcomes. Some background The best treatment for melanoma remains to be determined, however surgery may be associated with a high cure rate. Patients...
Read MoreIn a nutshell This study analyzed outcomes in advanced skin cancer patients who stopped their treatment of nivolumab (Opdivo) and ipilimumab (Yervoy) due to side effects. This study concluded that many patients still benefit from the combination even after stopping treatment. Some background...
Read More
In a nutshell This study compared survival rates in advanced melanoma patients treated with either pembrolizumab (Keytruda) or ipilimumab (Yervoy). The study found that patients treated with pembrolizumab had a higher survival rate and fewer overall side effects. Some background...
Read More
In a nutshell This study aimed to investigate whether neoadjuvant systemic therapy (NST) influenced the eligibility of HER2 positive breast cancer patients to undergo breast conserving therapy (BCT). This study concluded the use of NST can result in patients who are non-eligible for BCT converting to patients that are eligible for BCT. Some...
Read More
In a nutshell This study reviewed the updated NCCN guidelines for the treatment of metastatic (spread to other parts of the body) melanoma. Some background New treatments have been developed in recent years for metastatic melanoma, particularly targeted and immunotherapies. These treatments are leading to improved response and survival in these...
Read More
